CytoMed Therapeutics Limited (NasdaqCM: GDTC)
Health Care · Biotechnology · SG
$0.88
-1.13% today · -67.3% 1Y
CytoMed Therapeutics Limited (NasdaqCM: GDTC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.50M and employs 42 people.
Over the last twelve months the share price has lost 67.3%, trading between 0.68 and 3.68.
Tweenvest scores CytoMed Therapeutics Limited across four factors: quality 38/100, value 33/100. Its strongest factor is quality.
GDTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.50M
- Revenue (TTM)
- $609.73K
- P/E
- —
- EPS
- -0.30
- Dividend yield
- —
- Beta (5Y)
- 0.07
- 52-week high
- $3.68
- 52-week low
- $0.68
- Avg volume (3M)
- —
- Shares outstanding
- 11.93M
- Employees
- 42
- Next earnings
- —
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
- ISIN
- SGXZ17669631
- Founded
- 2018
- Listed since
- Apr 14, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| IN8bio, Inc.NasdaqCM: INAB | $10.94M | $1.11 | -17.16% |
| Intensity Therapeutics, Inc.NasdaqCM: INTS | $10.94M | $3.35 | -7.71% |
| Cellectar Biosciences, Inc.NasdaqCM: CLRB | $10.78M | $1.14 | -21.38% |
| Noxopharm LimitedASX: NOX | $10.69M | AU$0.05 | -18.03% |
| Palatin Technologies, Inc.LSE: 0KF3 | $10.49M | $5.89 | +1.55% |
| Ceryvyn Therapeutics LimitedASX: CYV | $10.47M | AU$0.01 | -15.38% |
| Regentis Biomaterials Ltd.NYSEAM: RGNT | $10.47M | $1.49 | -6.88% |
| Tempest Therapeutics, Inc.NasdaqCM: TPST | $10.32M | $0.62 | -17.88% |
Figures last refreshed Oct 18, 2026.